XRCC1

Across TCGA pan-cancer cohorts, XRCC1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of XRCC1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where XRCC1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types XRCC1 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, LUAD, and LSCC are the cancer types where XRCC1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in XRCC1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	+0.384	<.001	10	view →
LUAD	Male	All	+0.422	<.001	9	view →
LSCC	Male	II,III,IV	+0.565	<.001	8	view →
PDAC	Female	II,III,IV	−0.335	<.001	8	view →
HNSC	Male	III,IV	+0.211	<.001	8	view →
OV	All	All	+0.321	.027	2	view →
CCRCC	Male	All	+0.050	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

XRCC1–COAD

Open the COAD breakdown →